03.05.24 -- What Does The Catalent Acquisition By Novo Holdings Mean For The Biopharma Industry?

Perhaps your company is located on, or considering expanding to, a biopharma or life-sciences campus. Ever wonder how these “campuses” (or “parks”) materialize? Jason Benson of JLL Life Sciences Real Estate Solutions explains to chief editor Louis Garguilo.

“Having been outsourcing to CDMOs for 20 years in the small molecule space, I see a distinct difference in technical performance compared to my mid-2000s CDMOs," says an executive. What's going on here?

Learn how the establishment of effective guidelines and standardization relevant to cell therapy development can help to minimize delays and lead to more positive outcomes.

Explore the benefits of working with a CDMO that has extensive plasmid experience and integrated project teams across the production process.

Finding a CDMO that can perform all the necessary testing for an AAV product can make a significant difference for a nascent company or novel drug.

Learn about strategies to meet the quality and regulatory requirements of cell and gene therapies and how to identify issues early on, reduce quality and compliance risks, and avoid delays and rework.

As developers begin their AAV therapy research, opting to conduct early phase studies with an experienced CDMO can help mitigate funding challenges and procure material for clinical data generation.

Augmented reality enables drug sponsors to provide remote assistance and direction to their manufacturing team during tech transfer, helping to reduce costs, streamline timelines, and improve the effectiveness of manufacturing processes.

Standardized methods, materials, and analytics are critical for overcoming hurdles in the gene therapy space. Explore how a platform approach to fast-track AAVs can enhance quality and efficiency.

LentiPeak, our suspension-based, scalable lentiviral vector production platform, enables efficient transition for cell and gene therapies from the preclinical stage through clinical development and commercialization.

Built on our revolutionary NxGen technology found in our NanoAssemblr family of instruments, the NanoAssemblr GMP System enables you to go from concept to clinic with speed and confidence.

Learn about the formation of Andelyn Biosciences and the creation of a small GMP facility to produce viral vectors. The talent and tenacity of the researchers paid off with the first FDA-approved systemic gene therapy.